The intended target audience for this program is US dermatologists and NP/PAs who treat patients with AA.
The goal of this program is for learners to demonstrate and improve their application of knowledge, clinical performance, and confidence in making treatment decisions to optimize the treatment of patients with AA.
Upon completion of this activity, participants should be able to:
Formulate an accurate diagnosis and classification of AA based on multiple disease and patient factors
Detail factors that may predict a patient’s positive or negative response to JAK inhibitor therapy for AA
Evaluate patients with AA for treatment candidacy with JAK inhibitor therapy
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Brittany Craiglow, MD
Associate Adjunct Professor
Department of Dermatology
Yale School of Medicine
New Haven, Connecticut
Brittany Craiglow, MD: consultant/advisor/speaker: AbbVie, Concert Pharmaceuticals, Incyte, Lilly, Pfizer, Regeneron, Sanofi-Genzyme.
Maryanne Makredes Senna, MD, FAAD
Assistant Professor of Dermatology
Harvard Medical School
Director, Lahey Hair Loss Center of Excellence
Lahey Hospital and Medical Center
Maryanne Makredes Senna, MD, FAAD: consultant/advisor/speaker: AbbVie, Eli Lilly, Kintor, L'Oréal, Pfizer.
The planners and content peer reviewers from Clinical Care Options, LLC and the National Alopecia Areata Foundation have no relevant financial relationships to disclose, except Douglas DiRuggiero, DMSc, MHS, PA-C as noted below:
Douglas DiRuggiero, DMSc, MHS, PA-C: consultant/advisor/speaker: Abbvie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, EPI Health, Incyte, Lilly, Novartis, Sanofi/Regeneron, Sun Pharmaceuticals, UCB.
Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 10, 2023, through October 09, 2024:
1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Alopecia Areata Foundation. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 contact hours.
Physician Associates Continuing Medical Education
Clinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 09, 2024. PAs should only claim credit commensurate with the extent of their participation.